Getinge reported mixed Q4 21 results, missing top-line expectations but beating on profits. Sales declined by 9.6%, largely attributable to ‘Acute care therapies’ (-22.1%). Adjusted EBITA margin (+100bp) leveraged productivity improvements and cost control, leading to a 33% hike in the dividend (SEK 4/share).
FY22 growth is expected to be at the higher end of 4-6%.
We will trim our top-line estimates, which will be partly offset by a margin upgrade in the forecast period, resulting in little c ....
02 Feb 2022
Q4 21 margin expansion offsets the top-line miss
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q4 21 margin expansion offsets the top-line miss
- Published:
02 Feb 2022 -
Author:
Virendra Chauhan -
Pages:
3
Getinge reported mixed Q4 21 results, missing top-line expectations but beating on profits. Sales declined by 9.6%, largely attributable to ‘Acute care therapies’ (-22.1%). Adjusted EBITA margin (+100bp) leveraged productivity improvements and cost control, leading to a 33% hike in the dividend (SEK 4/share).
FY22 growth is expected to be at the higher end of 4-6%.
We will trim our top-line estimates, which will be partly offset by a margin upgrade in the forecast period, resulting in little c ....